Pacific Heights Asset Management LLC maintained its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 107,000 shares of the medical research company’s stock at the end of the first quarter. Amgen makes up 1.7% of Pacific Heights Asset Management LLC’s portfolio, making the stock its 16th largest position. Pacific Heights Asset Management LLC’s holdings in Amgen were worth $17,555,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in AMGN. National Pension Service boosted its stake in shares of Amgen by 0.9% in the first quarter. National Pension Service now owns 493,954 shares of the medical research company’s stock valued at $81,196,000 after buying an additional 4,169 shares during the last quarter. Carroll Financial Associates Inc. boosted its stake in shares of Amgen by 45.3% in the first quarter. Carroll Financial Associates Inc. now owns 7,912 shares of the medical research company’s stock valued at $1,298,000 after buying an additional 2,465 shares during the last quarter. LVM Capital Management Ltd. MI boosted its stake in shares of Amgen by 1.3% in the first quarter. LVM Capital Management Ltd. MI now owns 76,290 shares of the medical research company’s stock valued at $12,517,000 after buying an additional 1,000 shares during the last quarter. Stillwater Investment Management LLC boosted its stake in shares of Amgen by 2.6% in the first quarter. Stillwater Investment Management LLC now owns 16,204 shares of the medical research company’s stock valued at $2,659,000 after buying an additional 404 shares during the last quarter. Finally, Fenimore Asset Management Inc. purchased a new stake in shares of Amgen during the first quarter valued at approximately $207,000. 79.12% of the stock is owned by institutional investors and hedge funds.

Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.12% on Friday, hitting $169.74. The company had a trading volume of 1,510,790 shares. The company has a market capitalization of $123.85 billion, a P/E ratio of 15.46 and a beta of 1.35. The firm has a 50-day moving average price of $173.53 and a 200 day moving average price of $168.31. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the company earned $2.84 earnings per share. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities analysts expect that Amgen Inc. will post $12.57 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.71%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s payout ratio is currently 41.93%.

ILLEGAL ACTIVITY WARNING: “Pacific Heights Asset Management LLC Maintains Position in Amgen Inc. (AMGN)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/26/pacific-heights-asset-management-llc-maintains-position-in-amgen-inc-amgn.html.

Several equities research analysts recently commented on AMGN shares. Robert W. Baird reissued a “neutral” rating and issued a $165.00 price target on shares of Amgen in a research note on Friday, April 28th. Mizuho set a $195.00 price target on Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the company a “buy” rating in a research note on Tuesday, May 9th. Vetr raised Amgen from a “buy” rating to a “strong-buy” rating and set a $179.72 price target for the company in a research note on Thursday, May 11th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $180.00 price target on shares of Amgen in a research note on Monday, May 22nd. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $186.04.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.